BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cell News » Page 89

Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

Israel Continues to Cultivate Stem Cell Innovation as Cellect and Accellta Enter Into Collaborative Agreement

By Leave a Comment

In major news today, Cellect Biomed Ltd. and Accellta announced that they have signed an agreement to evaluate Cellect’s apoptotic induction based technology in combination with Accellta’s stem cell culturing technologies. Cellect Biomed Ltd. is headquartered in Tel Aviv, while Accellta is headquartered in Haifa, Israel.

Accellta is a fascinating stem cell company that can quickly, efficiently, and cost-effectively grow massive quantities of clinical grade cells in xeno-free, feeder-free culture, by utilizing methods of growing the cells in suspension. Specifically, the company can increase a cell population from 1 million cells to 10 billion cells in two weeks with a bi-weekly change of media and an overall cost of about $3,000, by using bioreactors to do it in a very efficient way. Using traditional adherent culture, this would take about 70 liters of medium and an overall cost of $150,000, because it would take 40 to 50 days to do the expansion. [Read more…]

Cord Blood Market Consolidation Continues as “FamilyCord” Acquires Southern Cord Inc.

By 1 Comment

On November 13, 2015, AlphaCord released news that it was acquiring LifeSource Cryobank. The acquisition was AlphaCord’s fifth acquisition of smaller cord blood banks. Today,  California Cryobank Stem Cell Services LLC, better known as “FamilyCord”, announced it has acquired Southern Cord Inc., a cord blood bank operating within the southeastern U.S.

Together, these recent mergers continue the trend of consolidation within the global cord blood banking market. [Read more…]

No Longer Just for Humans — Cord Blood Banking Now Available to Horses Too

By Leave a Comment

VetiCell, LLC, has announced that it is launching a proactive stem cell storage program for animals, in which it will collect stem cells from the umbilical cord of horses or from the reproductive tissues of dogs following spay or neuter.

VetiCell is a sister company to AlphaCord, a human cord blood bank, with the two companies having the same owner and staff.

Currently, there are a couple companies operating in the veterinary stem cell market that collect stem cells through invasive methods (adipose or bone marrow). However, VetiCell’s new model is to collect veterinary stem cells without surgery from the umbilical cord of horses or from reproductive tissues after canine spay and neuter. These methods require no additional invasive surgery to collect an animal’s stem cells.

Since 2006, BioInformant has been tracking the human stem cell banking market. Initially, the market was focused  on the storage of umbilical cord blood, although it has expanded over the past ten years to include the storage of other types of stem cells, including those present within cord tissue, dental pulp, adipose tissue, and more.

With hundreds of human cord blood banks now competing worldwide, it will be interesting to see whether any of them add equine cord blood banking to their portfolio of human stem cell storage services.

[Read more…]

Kirk, Manchin, Collins Introduce Bill to Speed Development of Regenerative Medicine

By 1 Comment

In major news released today, the Office of U.S. Senator for Illinois, Mark Kirk, announced the introduction of The REGROW Act, a bill designed to “reduce barriers to medical innovation and accelerate the development of new regenerative medicine treatments.”

The legislation could substantially support stem cell innovation, as it requires the “FDA to collaborate with stakeholders to develop standards that will lead to manufacturing processes and controls for safe regenerative medicine products.”

The ability of stakeholders to work collaboratively with the FDA has been a major hot topic lately, with a FDA Public Hearing to review four draft guidances controlling the regulation of stem cells recently postponed due to an unexpectedly large number of registrations (approximately 600). It is my opinion – and one that is shared by most advocacy groups – that the large turn-out for this FDA public hearing was a successful effort to communicate patient concerns to the FDA and a way to indicate that more input is needed in the regulatory process.

Most impressively, the REGROW Act is supported by leading groups within the regenerative medicine space, including: [Read more…]

Stemedica Receives Approval from Emory University to Initiate Alzheimer’s Disease Study with Adult Allogeneic Stem Cells

By Leave a Comment

Lausanne, Switzerland; February 24, 2016 — Stemedica International, SA, a Stemedica Cell Technologies, Inc., a subsidiary and leader in the development of innovative stem cell-based treatments for Alzheimer’s Disease announced today that it has received IRB approval from Emory University in Atlanta, Georgia to initiate a clinical study entitled, “A Phase IIa Multicenter, Randomized, Single-Blind, Placebo-Controlled, Crossover Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Human Mesenchymal Stem Cells in Subjects with Mild to Moderate Dementia Due to Alzheimer’s Disease.”

This study will enroll approximately 40 subjects diagnosed with mild to moderate dementia at least three months prior to enrollment, based on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) Alzheimer’s criteria.

“We are very excited to take this next step in our clinical plan to develop a treatment for this devastating disease,” says Nikolai Tankovich, M.D., Ph.D., President and Chief Medical Officer of Stemedica Cell Technologies and Executive Chairman for Stemedica International “Patients will be treated at Emory and additional trial sites to be announced.”

About Stemedica International S.A.

Stemedica International S.A. is a biotechnology company that develops therapeutic applications for the treatment and prevention of Alzheimer’s disease and vascular dementia. The company is a subsidiary of Stemedica Cell Technologies, Inc., a global biotechnology company that manufactures adult allogeneic stem cells. Stemedica International has the worldwide rights to manufacture and distribute the parent company’s allogeneic, ischemia-tolerant mesenchymal stem cell (itMSC) and ischemia-tolerant neural stem cell (itNSC) lines and stem cell factors for Alzheimer’s disease and vascular dementia indications. The company also has Swissmedic licenses to import, export and distribute Stemedica Cell Technologies’ cell lines worldwide for human use in approved clinical trials. Manufactured in compliance with cGMP standards, the stem cell lines have a unique, proprietary technology based on the expansion of cells in constant hypoxia, which provides critical benefits in terms of safety, efficacy and scalability. For more information, visit www.stemedica-intl.com.

About Stemedica Cell Technologies, Inc.

Stemedica Cell Technologies, Inc. is a specialty biopharmaceutical company that manufactures best-in-class, allogeneic, adult stem cells and stem cell-derived factors. The company is a government-licensed manufacturer of cGMP, clinical-grade stem cells currently used in clinical trials in the United States under FDA Investigational New Drug (IND) approval for chronic heart failure, cutaneous photoaging, ischemic stroke and Alzheimer’s disease. Stemedica’s products are also used by research institutions and hospitals outside of US under the auspices of international regulatory authorities for pre-clinical and clinical (human) trials. Stemedica is developing clinical trials for other indications using its adult, allogeneic stem cells. The company has headquarters in San Diego, California, and can be found online at www.stemedica.com.

Forward Looking Statements

This press release may contain forward-looking statements. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance and you are cautioned not to place undue reliance on these forward-looking statements. These statements reflect the views of Stemedica as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release.

Media and Business Contact
David Cheatham
Stemedica International S.A.
+41 (0)78 794 7232
dcheatham@stemedica.com

Want to be better informed than your competition? Get future stem cell industry updates.

 

About Us

BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.

Click here to view our global strategic reports for the stem cell and cord blood industry.

BioInformant's World-Class Clients